| Title |
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
|
|---|---|
| Published in |
OncoTargets and therapy, November 2018
|
| DOI | 10.2147/ott.s160358 |
| Pubmed ID | |
| Authors |
Yi-Long Wu, Chong-Rui Xu, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Angela Märten, Jean Fan, Barbara Peil, Caicun Zhou |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 11% |
| Other | 4 | 9% |
| Student > Bachelor | 3 | 7% |
| Student > Doctoral Student | 3 | 7% |
| Student > Master | 3 | 7% |
| Other | 6 | 14% |
| Unknown | 20 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Neuroscience | 2 | 5% |
| Unspecified | 1 | 2% |
| Other | 5 | 11% |
| Unknown | 17 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2019.
All research outputs
#16,279,421
of 25,707,225 outputs
Outputs from OncoTargets and therapy
#904
of 3,013 outputs
Outputs of similar age
#210,230
of 364,643 outputs
Outputs of similar age from OncoTargets and therapy
#53
of 146 outputs
Altmetric has tracked 25,707,225 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,013 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,643 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 146 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.